2021 should be a banner year for biotech startups that make smart choices early – TechCrunch
John Flavin Contributor John Flavin is founder and CEO of Portal Innovations, LLC. Last year was a record 12 months for venture-backed biotech and pharma companies, with deal activity rising to $28.5 billion from $17.8 billion in 2019. As vaccines roll out, drug development pipelines return to normal, and next-generation therapies continue to hold investor interest, 2021 is on pace to be another blockbuster year. The median step up in valuations from seed to Series A is now 2x, higher than in all later rounds. As a result, biotech startups will continue to attract more investm...
Source: techcrunch.com
